Priorities among HIV-positive individuals for tuberculosis preventive therapies

H. Y. Kim, C. F. Hanrahan, D. W. Dowdy, N. A. Martinson, J. E. Golub, J. F.P. Bridges

Research output: Contribution to journalArticlepeer-review


BACKGROUND: There has been slow uptake of isoniazid preventive therapy (IPT) among people living with HIV (PLWH). METHODS: We surveyed adults recently diagnosed with HIV in 14 South African primary health clinics. Based on the literature and qualitative interviews, sixteen potential barriers and facilitators related to preventive therapy among PLWH were selected. Best-worst scaling (BWS) was used to quantify the relative importance of the attributes. BWS scores were calculated based on the frequency of participants’ selecting each attribute as the best or worst among six options (across multiple choice sets) and rescaled from 0 (always selected as worst) to 100 (always selected as best) and compared by currently receiving IPT or not. RESULTS: Among 342 patients surveyed, 33% (n ¼ 114) were currently taking IPT. Having the same standard of life as someone without HIV was most highly prioritized (BWS score ¼ 67.3, SE ¼ 0.6), followed by trust in healthcare providers (score, 66.3 6 0.6). Poor standard of care in public clinics (score, 30.6 6 0.6) and side effects of medications (score, 33.7 6 0.6) were least prioritized. BWS scores differed by IPT status for few attributes, but overall ranking was similar (spearman’s rho ¼ 0.9). CONCLUSION: Perceived benefits of preventive therapy were high among PLWH. IPT prescription by healthcare providers should be encouraged to enhance IPT uptake among PLWH.

Original languageEnglish (US)
Pages (from-to)396-402
Number of pages7
JournalInternational Journal of Tuberculosis and Lung Disease
Issue number4
StatePublished - Apr 1 2020


  • Choice experiment
  • Isoniazid preventive therapy
  • Patient preferences

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases


Dive into the research topics of 'Priorities among HIV-positive individuals for tuberculosis preventive therapies'. Together they form a unique fingerprint.

Cite this